Enanta Pharma (ENTA) Tops Q3 EPS by 4c. Revs Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Enanta Pharmaceuticals (ENTA) PT Raised to $38 at JPMorgan
August 8, 2017 8:45 AM EDTJPMorgan raised its price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $38.00 (from $32.00) while maintaining a Overweight rating.
... MoreEnanta Pharmaceuticals (ENTA) PT Raised to $36 at Baird; Remains Sidelined
August 8, 2017 7:19 AM EDTBaird raised its price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $36.00 (from $27.00) while maintaining a Neutral rating following the company's 3Q. AbbVie's reported sales of $225M for Viekira were largely in line with estimates. Enanta earned $7.5M in royalty revenue on these sales, versus... More
